Clinical Trials Logo

Memory Disorders clinical trials

View clinical trials related to Memory Disorders.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT00457769 Active, not recruiting - Stroke Clinical Trials

Aricept to Improve Functional Tasks in Vascular Dementia

Start date: May 2007
Phase: Phase 1
Study type: Interventional

Medications for memory improvement are available but they may not actually improve the ability to do real world tasks. The purpose of this research study is to determine if a medicine used to treat memory problems donepezil(Aricept) enhances the ability to remember steps of functional tasks and the actual ability to perform tasks relevant to real-life independence. Aricept is an FDA approved medication for the treatment of Alzheimer's disease. Aricept is an investigational drug for the purposes of this study, and is not approved for this purpose.

NCT ID: NCT00091468 Active, not recruiting - Clinical trials for Age-Related Memory Disorders

Nicotine Treatment of Mild Cognitive Impairment (MCI)

Start date: September 2003
Phase: Phase 1
Study type: Interventional

The purpose of this 12-month study is to determine whether nicotine, administered in the form of nicotine patches, can improve symptoms of memory loss in some people experiencing mild memory problems (referred to in this study as "mild cognitive impairment" or MCI).

NCT ID: NCT00031018 Active, not recruiting - Alzheimer's Disease Clinical Trials

Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha

Start date: n/a
Phase: Phase 2
Study type: Interventional

In this phase I-II parallel design, randomized, double-blind clinical trial we will determine if 3,000 or 30,000 units ingested hrIFN-a prevents deterioration of cognitive functioning in patients with dementia of Alzheimer's type (AD) and whether ingested hrIFN-a treatment decreases acute phase reactants and pro-inflammatory cytokine IL-6 in mild to moderate AD. We predict that the novel anti-inflammatory agent ingested human recombinant interferon alpha (hrIFN-a) will modulate inflammation and inhibit the natural history of AD progression. If you are eligible, you will receive Aricept for 5 weeks (donezepil) and thereafter in addition to Aricept either placebo (inactive substance) or interferon alpha at 3,000 or 30,000 units every day for 12 months.